Another Denosumab Deal For mAbxience In MEA
MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
You may also be interested in...
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.
Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.